Megron 50 Er Tablet

Megron 50 Er Tablet সম্পর্কে

Megron 50 হলো Mirabegron-এর একটি ব্র্যান্ড, শক্তি ৫০ mg, Er Tablet আকারে। Mirabegron-এর অন্য ব্র্যান্ডগুলো এই পাতায় কম দাম থেকে সাজানো আছে, দাম তুলনা করতে পারবেন। এটি তৈরি করে Opsonin Pharma Limited। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।

Mirabegron-এর ১০টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Betmira ER 25 mg Tablet (Extended Release)-এর, প্রতি ইউনিট ৳ ৩০.০০।

Megron 50 Er Tablet কী?

Megron 50 is a er tablet from Opsonin Pharma Limited, with the generic name Mirabegron. Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. The doctor decides the dose and course.

Megron 50-এর ব্যবহার

Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Your doctor will decide if it is suitable for you.

Megron 50 কীভাবে ব্যবহার করবেন

Swallow the er tablet with water. Megron 50 is taken by mouth. Take Megron 50 as your doctor tells you. Do not change the dose or stop early without asking your doctor. If you miss a dose, ask your doctor or pharmacist what to do.

Megron 50-এর পার্শ্বপ্রতিক্রিয়া

Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.

সতর্কতা ও নিরাপত্তা

Hypertension : Mirabegron can increase blood pressure. Mirabegron is not recommended during pregnancy and in women is planning to be pregnant. Mirabegron is excreted in the milk of rodents and therefore is predicted to be present in human milk. Keep out of reach of children.

সাধারণ প্রশ্ন

Why is Megron 50 prescribed?

Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Your doctor will decide if it is suitable for you.

How should I take Megron 50?

Swallow the er tablet with water. Megron 50 is taken by mouth.

What are the side effects of Megron 50?

Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.

Is Megron 50 safe for everyone?

Hypertension : Mirabegron can increase blood pressure. Mirabegron is not recommended during pregnancy and in women is planning to be pregnant.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Mirabegron is the first beta-3 adrenoceptor agonist. Mirabegron exerts its effect via a dual mechanism, both directly acts on the bladder smooth muscle and also via the sensory nervous system, it increases the levels of cyclic adenosine monophosphate (cyclic AMP) and leads to relaxation of the detrusor smooth muscle during storage phase of urinary bladder fill-void cycle by activation of beta-3 adrenoceptor which increase bladder capacity.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Adults including elderly: The recommended starting dose is Mirabegron 25 mg tablet once daily with or without food. Based on individual patient efficacy and tolerability the dose may be increased to Mirabegron 50 mg tablet once daily.

Renal or hepatic impairment:
  • Patients with severe renal impairment (ClCr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B), the daily dose of Mirabegron should not exceed 25 mg tablet once daily.
  • Mirabegron has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child Pugh Class C) and it is therefore not recommended for use in these patient populations.
Gender: No dose adjustment is necessary according to gender.

Paediatric population: The safety and efficacy of Mirabegron in children below 18 years of age have not yet been established.

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Effect of enzyme inhibitors: Mirabegron exposure (AUC) was increased 1.8-fold in the presence of the strong inhibitor of CYP3A/P-gp ketoconazole in healthy volunteers. No dose adjustment is needed when Mirabegron is combined with inhibitors of CYP3A and/or P-gp. However, in patients with mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors, such as itraconazole, ketoconazole, ritonavir and clarithromycin, the recommended dose is 25 mg once daily with or without food. Mirabegron is not recommended in patients with severe renal impairment or patients with moderate hepatic impairment concomitantly receiving strong CYP3A inhibitors.

Effect of enzyme inducers: Substances that are inducers of CYP3A or P-gp decrease the plasma concentrations of Mirabegron. No dose adjustment is needed for Mirabegron when administered with therapeutic doses of rifampicin or other CYP3A or P-gp inducers.

Effect of Mirabegron on CYP2D6 substrates: In healthy volunteers, the inhibitory potency of Mirabegron towards CYP2D6 is moderate and the CYP2D6 activity recovers within 15 days after discontinuation of Mirabegron. Multiple once daily dosing of Mirabegron IR resulted in a 90% increase in Cmax and a 229% increase in AUC of a single dose of metoprolol. Multiple once daily dosing of Mirabegron resulted in a 79% increase in Cmax and a 241% increase in AUC of a single dose of desipramine. Caution is advised if Mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6, such as thioridazine, Type 1 C antiarrhythmics (e.g., flecainide, propafenone) and tricyclic antidepressants (e.g., imipramine, desipramine). Caution is also advised if Mirabegron is co-administered with CYP2D6 substrates that are individually dose titrated.

Effect of Mirabegron on transporters: Mirabegron is a weak inhibitor of P-gp. Mirabegron increased Cmax and AUC by 29% and 27%, respectively, of the P-gp substrate digoxin in healthy volunteers. For patients who are initiating a combination of Mirabegron and digoxin, the lowest dose for digoxin should be prescribed initially. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect.

Other interactions: No clinically relevant interactions have been observed when Mirabegron was co-administered with therapeutic doses of solifenacin, tamsulosin, warfarin, metformin or a combined oral contraceptive medicinal product containing ethinylestradiol and levonorgestrel. Dose-adjustment is not recommended.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Mirabegron is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients and severe uncontrolled hypertension defined as systolic blood pressure 180 mm Hg and/or diastolic blood pressure 110 mm Hg.

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

The most common side effects reported for patients treated with Mirabegron 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections. The frequency of tachycardia was 1.2% in patients receiving Mirabegron 50 mg. Tachycardia led to discontinuation in 0.1% patients receiving Mirabegron 50 mg. The frequency of urinary tract infections was 2.9% in patients receiving Mirabegron 50 mg. Urinary tract infections led to discontinuation in none of the patients receiving Mirabegron 50 mg. Serious adverse reactions included atrial fibrillation (0.2%).

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

There are limited amount of data from the use of Mirabegron in pregnant women. Studies in animals have shown reproductive toxicity. Mirabegron is not recommended during pregnancy and in women is planning to be pregnant. Mirabegron is excreted in the milk of rodents and therefore is predicted to be present in human milk. No studies have been conducted to assess the impact of Mirabegron on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child. Mirabegron should not be administered during breast-feeding. There were no treatment-related effects of Mirabegron on fertility in animals. The effect of Mirabegron on human fertility has not been established.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Renal impairment: Mirabegron has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m2 or patients requiring haemodialysis) and therefore, it is not recommended for use in this patient population. Data are limited in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2); based on a pharmacokinetic study a dose reduction to 25 mg is recommended in this population. Mirabegron is not recommended for use in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2) concomitantly receiving strong CYP3A inhibitors.

Hepatic impairment: Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in this patient population. Mirabegron is not recommended for use in patients with moderate hepatic impairment (Child-Pugh Class B) concomitantly receiving strong CYP3A inhibitors.

Hypertension: Mirabegron can increase blood pressure. Blood pressure should be measured at baseline and periodically during treatment with Mirabegron, especially in hypertensive patients. Data are limited in patients with stage 2 hypertension (systolic blood pressure 160 mm Hg or diastolic blood pressure 100 mm Hg).

Patients with congenital or acquired QT prolongation: Caution should be exercised when administering Mirabegron in patients with congenital or acquired QT prolongation.

Patients with bladder outlet obstruction and patients taking antimuscarinics medications for OAB: A controlled clinical safety study in patients with bladder outlet obstruction (BOO) did not demonstrate increased urinary retention in patients treated with Mirabegron; however, Mirabegron should be administered with caution to patients with clinically significant bladder outlet obstruction. Mirabegron should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB.

মাত্রাধিক্যতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Mirabegron has been administered to healthy volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations and increased pulse rate exceeding 100 beats per minute (bpm). Multiple doses of Mirabegron up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy volunteers. Treatment for overdose should be symptomatic and supportive. In the event of overdose, pulse rate, blood pressure, and ECG monitoring is recommended.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Store in a cool and dry place, protected from light.

বিকল্প ব্র্যান্ড: Mirabegron

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

Betmira ER Tablet (Extended Release)

25 mg

Mirabegron

Healthcare Pharmaceuticals Ltd.

৳ ২৯.৪ ৳ ৩০.০০ ২% ছাড় প্রতি ইউনিট

Betmira ER Tablet (Extended Release)

50 mg

Mirabegron

Healthcare Pharmaceuticals Ltd.

৳ ৫৩.৯ ৳ ৫৫.০০ ২% ছাড় প্রতি ইউনিট

Megron Er Tablet

25 mg

Mirabegron

Opsonin Pharma Limited

দাম দেওয়া নেই

Miragon 50 Er Tablet

50 mg

Mirabegron

Advanced Chemical Industries PLC

দাম দেওয়া নেই

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।